In the spring of Beijing, the annual meeting of Chinese Pathologists was grandly convened. On the afternoon of March 30th, Dunwill Medical held a Symposium at the National Convention Center in Beijing, titled "Intelligent Pathology - Focusing on the Translational Research and Application of Chinese Original Pathological Biomarkers". Together with experts in the field of pathology, they exchanged cutting-edge technologies in the field of pathology, discussed the difficulties and future prospects of innovative translation of Chinese original pathological biomarkers, and presented a professional and exciting academic feast for everyone.

Firstly, Professor Chen Gang, Director of the Pathology Department of Fujian Cancer Hospital, delivered the opening speech for the meeting. He said that today's discussion on the difficulties and prospects of innovative development of pathological markers is an important issue related to the development of precision medicine. The research and development of pathological biomarkers provide strong scientific support for early detection, accurate diagnosis, formulation of personalized treatment plan, and evaluation of treatment effectiveness of diseases. However, in the process of transitioning from laboratory to clinical practice, we face challenges in technology transformation, clinical implementation, ethics, and economics. Therefore, we need many like-minded companies to grow together with clinical practice in this process. We hope to see more original products discovered and successfully developed in the field of pathology after this meeting, which will help build high-level hospitals in the long run.

Dr. Zhang Xinyi from the Pathology Department of Zhongshan Hospital affiliated to Fudan University gave a keynote speech titled "Research on the Application Value of Y2 Molecule in Thyroid Tumors", sharing the discovery path and exciting stories behind the discovery of the original Chinese biomarker Y2 antibody. Dr. Zhang introduced that thyroid tumors are the most common type of tumor in the daily diagnosis of pathologists. Currently, the immunohistochemical indicators widely used in clinical practice, such as Galectin-3, have certain limitations in clinical application. Therefore, it is necessary to explore a more sensitive and specific biomarker to assist in diagnosis. Research has found that Y2 molecule is a highly potential differential diagnostic indicator for papillary carcinoma, and for the first time, a combination of Y2, Galectin-3, and BRAF V600E has been proposed as a differential diagnostic indicator for papillary carcinoma, improving its diagnostic efficiency. Dr. Zhang further introduced the exploration of expression in various thyroid tumors and found that Y2 is a potential immunohistochemical marker for distinguishing IFVPTC from thyroid tumors with various follicular structures as the main component; In addition, the expression of Y2 in myeloid carcinoma is positively correlated with pathological grading, and advanced myeloid carcinoma often shows positive expression of Y2; Myeloid carcinoma expressing Y2 shows a trend of poor prognosis, especially in the early postoperative stage. This short-term prognostic stratification provides a reference for active adjuvant therapy in clinical practice, and therefore has important clinical significance. Finally, Dr. Zhang summarized that Y2 molecule has good differential diagnostic value and certain prognostic value in thyroid tumors, making it a very promising clinical diagnostic indicator. At present, the Y2 antibody is in the process of development and declaration, and the reagent kit has been preliminarily formed.

In the subsequent roundtable discussion, Professor Lin Dongmei, Director of the Pathology Department of Peking University Cancer Hospital, Professor Sheng Weiqi, Director of the Medical Department of Fudan University Affiliated Cancer Hospital, Professor Hou Yingyong, Director of the Pathology Department of Fudan University Affiliated Zhongshan Hospital, and Dr. Li Yongmei from Roche Diagnostic Products (Shanghai) Co., Ltd. conducted in-depth discussions on the topic of "Obstruction and Long Path, Discussing the Challenges and Prospects of the Original Research Road of Innovative Pathological Biomarkers". As authoritative experts in the domestic pathology field, they introduced the direction of original biomarkers that have been the most concerned in clinical diagnosis and research in recent years, as well as their rich experience in exploring and applying innovative biomarkers, as well as some challenges encountered. Experts say that currently, there are many biomarkers emerging in both diagnosis and treatment, and they are increasingly being used in clinical practice, but they still cannot meet the current demand for precise diagnosis and treatment. A large part of the original research biomarkers come from results obtained from basic research on clinical practical problems. How to translate these results, ultimately implement and apply them to clinical practice is a very long and complex process that requires a strong research and development team; And the subsequent patent applications, product commercialization, registration and application, clinical promotion, and a series of large and tedious tasks are a great challenge for laboratory staff. Therefore, we need to explore a good clinical transformation path and achieve it through the joint efforts of pathologists and basic research workers, as well as clinical doctors and enterprises. The wonderful sharing and insightful opinions of the experts have received warm feedback from the attending guests. It is their continuous exploration and efforts in the pathology industry that are driving innovative biomarkers into more cutting-edge fields.

At the same time, Dunwill Medical participated in the exhibitions with digital pathology workflow solution such as the D-Mind DigitPatho panoramic digital pathology image analysis platform, attracting the attention of many industry experts, scholars, and partners. The atmosphere of on-site communication, consultation, and negotiation was lively. Dunwill Medical will continue to provide customers with professional pathological product and solutions.

Dunwill Medical has always been committed to the discovery, development, and commercialization of innovative original biomarker, driven by clinical needs, utilizing multi-omics technology, an innovative medical industry model with close cooperation and collaborative development across multiple platforms has been formed. Pathological markers have brought new directions and more choices for clinical diagnosis, and Dunwill has also cooperated with multiple hospitals to explore new breakthroughs and directions for the innovative development of pathological biomarkers. 

We look forward to more Chinese original research and innovative biomarkers being utilized in the field of pathology in the future, achieving more breakthroughs and achievements, and promoting the intelligent  and high-quality development of pathological diagnosis in China.